Celgene Corp. buy tamam
Start price
19.03.17
/
50%
€113.26
Target price
12.11.18
€127.22
Performance (%)
-41.19%
End price
12.11.18
€66.61
Summary
This prediction ended on 12.11.18 with a price of €66.61. Massive losses of -41.19% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | 1,72 % | 3,37 % | 5,89 % | 52,38 % |
| iShares Nasdaq 100 | -4,56 % | -4,24 % | 21,39 % | 72,45 % |
| iShares Nikkei 225® | -7,12 % | -11,87 % | 42,36 % | 57,58 % |
| iShares S&P 500 | -0,89 % | 1,69 % | 19,49 % | 62,15 % |
Comments by tamam for this prediction
In the thread Celgene Corp. diskutieren
Celgene is a true "buy & hold" name in the biotech sector
tamam stimmt am 19.03.2017 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 141.04$ zu.
(Vom Mitglied beendet)